Bristol Myers Secures EU Approval for Opdivo in Lung Cancer Therapy

Published 3 hours agoBMY

Bristol Myers Secures EU Approval for Opdivo in Lung Cancer Therapy

Bristol Myers Squibb has received approval from the European Commission to use its Opdivo (nivolumab) in combination with platinum-based chemotherapy for treating certain lung cancer patients. This treatment specifically targets adults with resectable non-small cell lung cancer (NSCLC) who exhibit a high risk of recurrence and have a tumor cell PD-L1 expression of 1% or greater.

This approval stems from the promising results of the Phase 3 CheckMate -816 trial, where Opdivo and chemotherapy combination before surgery was shown to improve event-free survival and pathologic complete response when compared to chemotherapy alone. Notably, this marks the first time an immunotherapy-based option has been approved in the EU for neoadjuvant treatment of patients with resectable NSCLC, according to Nasdaq.

Dr. Nicolas Girard, a thoracic oncology professor, highlighted the potential of this development to enhance treatment strategies for non-metastatic NSCLC and reduce cancer recurrence risks post-surgery. Following this milestone, Bristol Myers's stock saw a rise, trading at $45.81 USD, marking a 3.82% increase. This move reflects the company's ongoing commitment to providing advanced treatment options in the European market.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Apple Blocks Fortnite's Return, Leaving iOS Gamers in Limbo

Apple Blocks Fortnite's Return, Leaving iOS Gamers in Limbo

12 minutes agoAAPL

Apple has blocked the return of Fortnite to the App Store, making it unavailable on iOS devices worldwide. Epic Games announced that Apple rejected its latest submission, preventing the game’s release not only in the U.S. but also on the Epic Games Store for iOS in the European Union. This move marks the latest chapter in the ongoing legal tug-of-war that started in 2020 when Epic accused Apple of antitrust violations over its 30% commission on in-app purchases. According to Reuters, despite a 2021 court ruling that required Apple to allow alternative in-app payment options, Apple introduced a new system with a revised 27% commission rate, leading to further legal disputes. Recently, a judge ruled against Apple’s practices, forbidding them from collecting commissions via these alternative systems. Meanwhile, Epic Games has been encouraging users to utilize its own payment system, offering a 20% rebate in Epic Rewards to steer users away from Apple’s payment model. While Epic battles for these changes, iOS users remain caught in the crossfire, stuck with outdated Fortnite versions and limited access. As the dispute carries on, it leaves the gaming community waiting for a resolution.

Baird Lowers Intuitive Surgical's Price Target but Maintains Optimism

Baird Lowers Intuitive Surgical's Price Target but Maintains Optimism

27 minutes agoISRG

Baird has adjusted its price target for Intuitive Surgical from $707 down to $600, while maintaining an 'Outperform' rating on the company's stock. This development comes as analysts evaluate the company's strategic positioning and long-term growth prospects. David Rescott, an analyst at Baird, noted that despite the reduction in the price target, Intuitive Surgical remains well-positioned in the market under the leadership of CEO Gary S. Guthart. The company has shown resilience in the face of various challenges and is expected to continue its strong momentum, according to reports from marketscreener.com. In a move to bolster its market presence, Intuitive Surgical is keen on expanding into emerging markets, with a particular focus on India. The growing demand for robotic-assisted surgeries in these regions is a significant part of the company's strategy to maintain its competitive edge. The Economic Times highlighted this focus as part of Intuitive Surgical's broader narrative of growth and adaptability.

Boeing Close to Non-Prosecution Deal Over 737 MAX Crashes

Boeing Close to Non-Prosecution Deal Over 737 MAX Crashes

42 minutes agoBA

Boeing is reportedly on the verge of securing a non-prosecution agreement with U.S. prosecutors, which would help the aviation giant avoid a guilty plea in the criminal fraud case linked to the tragic 737 MAX crashes. This agreement, if confirmed, would also avert a trial set for June 23, 2025, concerning allegations that Boeing misled regulators about a crucial flight control system, according to a report by Reuters. The potential agreement requires judicial approval and is not yet finalized. Victims' families have voiced their disappointment with the proposed deal, believing Boeing should be held accountable in a courtroom for its involvement in the fatal accidents. The company's troubles stem from previous controversies, including a rejected plea deal where Boeing had agreed to pay a $487.2 million fine. The deal was dismissed last December due to issues related to a diversity provision in the selection of an independent monitor, as reported by the Associated Press. Boeing's strategy appears to focus on settling legal challenges following the crashes while avoiding additional courtroom battles. Despite the criticism from victims' families, Boeing remains committed to resolving outstanding legal issues, although the proposed non-prosecution agreement still requires final approval from a judge.

Macy's Increases Quarterly Dividend by 5%

Macy's Increases Quarterly Dividend by 5%

57 minutes agoM

Macy's, Inc. has announced a 5% boost in its quarterly dividend, now set at $0.1824 per share, which marks an increase from the previous $0.1737 per share. This dividend is scheduled for payment on April 1, 2025, with the record date for shareholders on March 14, 2025. The annualized dividend now stands at $0.73 per share, providing a yield of approximately 5.45%, according to Marketbeat. The payout ratio is reported at 29.4%, demonstrating that the dividend is well-supported by the company's earnings. This increase signals Macy's ongoing dedication to enhancing shareholder value through consistent dividend growth. As noted on their investor relations site, the company's financial strategies continue to focus on returning capital to investors.